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Background: Many promising anticancer molecules are abandoned during the course from bench to bedside due
to lack of clear-cut efficiency and/or severe side effects. Vitamin K3 (vitK3) is a synthetic naphthoquinone exhibiting
significant in vitro and in vivo anticancer activity against multiple human cancers, and has therapeutic potential
when combined with other anticancer molecules. The major mechanism for the anticancer activity of vitK3 is the
generation of cytotoxic reactive oxygen species (ROS). We thus reasoned that a rational redox modulation of cancer
cells could enhance vitK3 anticancer efficiency.
Methods: Cancer cell lines with peroxiredoxin 1 (PRX1) gene transiently or stably knocked-down and corresponding
controls were exposed to vitK3 as well as a set of anticancer molecules, including vinblastine, taxol, doxorubicin,
daunorubicin, actinomycin D and 5-fluorouracil. Cytotoxic effects and cell death events were evaluated by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based assay, cell clonogenic assay, measurement of
mitochondrial membrane potential and annexin V/propidium iodide double staining. Global ROS accumulation
and compartment-specific H2O2 generation were determined respectively by a redox-sensitive chemical probe
and H2O2-sensitive sensor HyPer. Oxidation of endogenous antioxidant proteins including TRX1, TRX2 and
PRX3 was monitored by redox western blot.
Results: We observed that the PRX1 knockdown in HeLa and A549 cells conferred enhanced sensitivity to
vitK3, reducing substantially the necessary doses to kill cancer cells. The same conditions (combination of
vitK3 and PRX1 knockdown) caused little cytotoxicity in non-cancerous cells, suggesting a cancer-cell-selective
property. Increased ROS accumulation had a crucial role in vitK3-induced cell death in PRX1 knockdown cells.
The use of H2O2-specific sensors HyPer revealed that vitK3 lead to immediate accumulation of H2O2 in the
cytosol, nucleus, and mitochondrial matrix. PRX1 silencing significantly up-regulated mRNA and protein levels
of NRH:quinone oxidoreductase 2, which was partially responsible for vitK3-induced ROS accumulation and
consequent cell death.
Conclusion: Our data suggest that PRX1 inactivation could represent an interesting strategy to enhance
cancer cell sensitivity to vitK3, providing a potential new therapeutic perspective for this old molecule.
Conceptually, a combination of drugs that modulate intracellular redox states and drugs that operate through
the generation of ROS could be a new therapeutic strategy for cancer treatment.
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Vitamin K3 (2-methyl-1, 4 naphthoquinone, also
known as menadione) is a form of vitamin K that
does not participate in the synthesis of coagulation
proteins [1, 2]. Rather, vitamin K3 (vitK3) is readily
redox cycled, thereby generating reactive oxygen spe-
cies (ROS) and consuming NADPH. VitK3 exhibits
anticancer activity against a variety of human cancer
cell lines [3–6]. The association of vitK3-induced cell
death with the cellular depletion of glutathione,
NADPH oxidation, the occurrence of macromolecular
damage, and the disruption of calcium homeostasis,
support the notion that the anticancer activity of
vitK3 is linked to oxidative stress [3, 7–9].
The encouraging results obtained in cell models re-
garding vitK3 anticancer activity have prompted several
in vivo investigations. A clinical phase I study showed
that vitK3 is reasonably well-tolerated, and the concen-
trations that are required for suppressing tumor growth
in vitro are clinically achievable [3, 10]. On the basis of
the synergistic cytotoxicity between vitK3 and other an-
ticancer drugs such as mitomycin C, vitamin C, or radi-
ation in vitro [2], clinical trials evaluating the
therapeutic effect of these combinations have been car-
ried out. An early study showed that vitK3 potentiates
radiation efficiency in patients with buccal carcinoma
[3], but a clinical phase II trial of vitK3 and mitomycin
C combination in advanced lung cancer patients and
gastrointestinal cancer patients failed to demonstrate
benefit [2, 11]. However, a clinical phase I/IIa study of
the combination of vitK3 and vitamin C in a group of
end stage prostate cancer patients who failed standard
therapy showed a strong synergistic effect [12]. Taken
together, these mixed results indicate that the cancer
types, doses of vitK3 and its combination with other
drugs, influence the effectiveness of vitK3 as an adjuvant
or co-adjuvant in chemotherapy. Additional studies are
clearly warranted to optimize the anticancer therapeutic
effect of vitK3 and to minimize its toxic side effects.
ROS generation is considered as a key mechanism of
vitK3-induced cell death [2, 13], and ROS-mediated can-
cer cell killing is receiving increasing attention [14–16].
However, due to the presence of oxidative stress adaptive
mechanisms, the use of ROS-generating agents alone may
not be sufficient to efficiently kill cancer cells. Therefore,
combinations of ROS-generating agents with compounds
capable of abrogating cellular antioxidant defense systems
are likely to have an additive or even synergistic effect.
This approach might be particularly useful for the treat-
ment of drugs-resistant cancer cells that have become
adapted to stress. We thus reasoned that redox modula-
tion of cancer cells through peroxiredoxin 1 (PRX1)
knockdown could enhance the anticancer activity of vitK3.
Peroxiredoxins constitute a large family of thiol-basedperoxidases that reduce peroxides with electrons donated
by thioredoxin 1 (TRX1) [17, 18], and PRX1 is the most
abundant of the six human peroxiredoxins. Importantly,
PRX1 is not only important for cellular peroxide scaven-
ging, but also regulates numerous signaling pathways via
direct protein-protein interaction with, for instance,
ASK1, GSTpi-JNK, AR, PTEN and c-ABL [19–21], or by
modulating H2O2 signaling [21]. PRX1 is frequently over-
expressed in various cancer cells including lung, bladder,
liver, thyroid, and breast cancers [22–24], and its over-
expression has been associated with carcinogenesis, me-
tastasis and resistance to radiotherapy or chemotherapy
[22, 23, 25]. In the present study, we observed that PRX1
knockdown (transient or stable silencing) enhanced the
toxic effect of vitK3 on cancer cells (A549 and HeLa) with
little or no effect on non-transformed immortalized cells
and primary fibroblasts. This selective cytotoxicity in
PRX1 knockdown cancer cells is associated with a signifi-
cant cellular accumulation of H2O2 partially due to an
overexpression of NRH:quinone oxidoreductase 2
(NQO2). PRX1 inactivation could represent an interesting
strategy to enhance cancer cell sensitivity to vitK3, provid-




VitK3, N-ethylmaleimide (NEM), N-acetyl-L-cysteine
(NAC), dimethyl sulfoxide (DMSO), dithiothreitol (DTT),
H2O2 and trichloroacetic acid (TCA) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Vinblastine,
taxol, doxorubicin, daunorubicin, actinomycin D and 5-
fluorouracil were from Enzo Life Sciences (Villeurbanne,
France). Hygromycin B, 6-carboxy-2',7'-dichlorodihy-
drofluorescein diacetate (carboxy-H2DCFDA), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), crystal violet, Vybrant Apoptosis Assay Kit
#3, propidium iodide (PI), tetramethylrhodamine methyl
ester (TMRM), 4-acetamido-4’-maleimidylstilbene-2,2’-
disulfonic acid (AMS) were from Life Technologies
(Eugene, OR, USA). The following antibodies were used:
anti-PRX1 (AbFrontier, Seoul, Korea); anti-PRX3
(Abcam, Cambridge, MA, USA); anti-TRX2 (R&D Sys-
tems, Minneapolis, MN, USA); anti-NQO2 (Proteintech,
Chicago, IL, USA); anti-GFP (Life Technologies); anti-β-
actin (Santa Cruz Biotechnology); anti-α-tubulin (Sigma-
Aldrich) and anti-TRX1 (Cell Signaling Technology,
Danvers, MA, USA). ON-TARGETplus SMARTpool
small interfering RNA (siRNA) targeting PRX1 (siPrx1),
and non-targeting pool control siRNA (siCon) were from
Dharmacon (Lafayette, CO, USA). Mammalian expression
vectors encoding HyPer targeted to cytosol, nucleus and
mitochondria were purchased from Evrogen (Moscow,
Russia).
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Human cervical adenocarcinoma HeLa and human lung
cancer A549 cell lines were from American Type Cul-
ture Collection (ATCC, Manassas, VA, USA) and were
cultured in standard Dulbecco’s modified Eagle’s
medium (DMEM) with 10 % fetal bovine serum (FBS).
Human vascular endothelial cell line HUVEC was from
ATCC and cultured in standard DMEM with 10 % FBS.
Primary normal dermal fibroblasts from ATCC were
kindly provided by Dr. Matthieu Gratia (UMR3348
CNRS-Institut Curie, Orsay, France) and cultured in
DMEM with 20 % FBS. The HeLa cells stably knocked-
down for PRX1 gene (PRDX1 HeLa SilenciX, designated
as Prx1– cells) and non-silenced control cells (Control
HeLa SilenciX, designated as Prx1+ cells) were pur-
chased from tebu-bio (Le Perray en Yvelines, France)
and were cultured in DMEM supplemented with 50 μg/
mL hygromycin B and 10 % FBS. All cell lines have been
characterized and the last cell line authentication has
been performed by eurofins (Ebersberg, Germany) using
PCR-single-locus technology after finalization of the
present study.
siRNA and plasmid transfection
For siRNA transfection, HeLa, A549 and HUVEC cells
and primary normal dermal fibroblasts were seeded at
density of 4 × 103 per well into a 96-well plate or at 1 ×
105 per well into a 6-well plate the day before transfec-
tion. Cells were then transfected with 5 nM siRNA (for
HeLa, A549 and HUVEC cells) or 15 nM siRNA (for
primary normal dermal fibroblasts) using INTERFERin
reagents (Polyplus Transfection, Illkirch, France) accord-
ing to the manufacturer’s instructions. Further experi-
ments were performed 48 h after transfection. For
HyPer transfection, HeLa cells were seeded at density of
4 × 105 per well into a 6-well plate the day before trans-
fection and were then transfected with 1 μg of HyPer
expressing vectors using jetPRIME reagents (Polyplus
Transfection).
Cell viability and cell death assays
MTT-based cell viability assay was performed as pre-
viously reported [26]. For cell clonogenic assay, ~300
cells per well were plated in 6-well plates and cul-
tured at 37 °C overnight. Cells were then treated with
indicated doses of vitK3 or DMSO (as vehicle con-
trol) for defined times followed by incubation in fresh
medium for another 10 days. The culture medium
was changed with fresh medium every 3 days. The
cells were then fixed and stained with 0.05 % crystal
violet in 70 % ethanol. The number of visible colonies
was counted manually. Mitochondrial membrane po-
tential (MMP) was monitored by TMRM staining, for
which cells were washed with PBS and incubated with10 nM TMRM for 30 min at 37 °C before being ana-
lyzed by flow cytometry. Fluorescent isothiocyanate
(FITC)-conjugated annexin V/PI double staining was
performed using the Vybrant Apoptosis Assay Kit #3
according to the manufacturer’s instructions. Cells
were analyzed in FL1-H (FITC) and FL2-H (PI) chan-
nels on flow cytometer equipped with CellQuest soft-
ware (FACSCalibur, Becton Dickinson).
Measurement of ROS
The general intracellular ROS was assessed using
carboxy-H2DCFDA. Briefly, cells were trypsinized, resus-
pended in medium without phenol red and serum, and
stained with 10 μM carboxy-H2DCFDA for 30 min at
37 °C in the dark. The cells were then washed in PBS,
collected and analyzed immediately by flow cytometry.
Microscopy imaging
Real-time imaging of the H2O2 dynamics was monitored
with the genetically encoded fluorescent probe HyPer
[27]. Fluorescent imaging in living cells was performed
using the microscope Leica DMI6000 B equipped with
Leica MM AF Imaging System. Images were acquired
using excitation filters YFPex (490–510 nm) and CFPex
(420–445 nm) and emission filter YFPem. Time-lapse
imaging was recorded every 10 s with Plan Fluotar dry
objective (magnification 40×, numerical aperture 0.6).
Images were then subtracted from background and fil-
tered with median method in ImageJ software (National
Institutes of Health, Bethesda, MD, USA). Ratio from
average fluorescence intensity of channel YFPex/YFPem
(F) divided by that of channel CFPex/YFPem (F0) was
calculated frame by frame, followed by normalization to
the value of images at start point of vitK3 treatment.
Western blotting and redox western blotting
For classic western blotting, cells were lysed in M-PER
protein extraction reagent (Pierce, Rockford, IL, USA)
supplemented with 0.5 mM DTT and complete protease
inhibitor cocktail (Roche Diagnostics, Mannheim,
Germany). Lysates were resolved by 4–12 % (for PAR
detection) or 12 % NuPAGE Bis-Tris gel (for other pro-
teins) with MOPS buffer (Life Technologies) under redu-
cing condition. Redox western blotting method was
previously described [26]. Briefly, cells in culture were
acid-quenched with ice-cold 10 % TCA, harvested,
washed with acetone and dissolved in lysis buffer
(100 mM Tris-Cl, 1 % SDS, 10 mM EDTA, pH 8.8) sup-
plemented with 30 mM AMS (for TRX1 and TRX2) or
25 mM NEM (for PRX3 and HyPer). Following 2 h incu-
bation under shaking at 37 °C (for AMS-treated sam-
ples) or 30 °C (for NEM-treated samples), insoluble
protein was removed by centrifugation. Each sample
containing about 30 μg of protein was separated by 4–
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Bis-Tris gel with MES buffer (for TRX1, TRX2 and
PRX3, Life Technologies) under non-reducing condition.
For both classic and redox western blotting, blots after
incubation with first antibodies were washed and probed
with IRDye 680- or IRDye 800cw-conjugated secondary
antibody (LI-COR Biosciences, Lincoln, NE, USA) and
then analyzed using an Odyssey Infrared Imaging System
(LI-COR). Scanned images and band integrated intensity
were analyzed and quantified by Odyssey v3.0 software.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated with RNeasy Protect Mini Kit
(Qiagen GmbH, Hilden, Germany). cDNA was generated
using iScript cDNA Synthesis Kit (Bio-Rad, Hercules,
CA, USA). Forward and reverse primers for GAPDH
and NQO2 genes were synthesized according to the se-
quence previously described [28, 29]. GAPDH served as
a reference gene for relative quantification. qRT-PCR
was performed with iQ SYBR Green Supermix (Bio-Rad)
in a CFX96 real-time PCR detection system (Bio-Rad).
Statistical analysis
All the values are the means ± SD of not less than three
measurements except indicated. Comparisons between
groups were analyzed using Student’s t-test. P values of
≤0.05 were considered significant.
Results
PRX1 knockdown confers selective sensitivity to vitk3 in
cancer cell lines
HeLa and A549 cancer cells were used to evaluate the
role of PRX1 in cancer cell resistance to vitK3. PRX1
was transiently depleted with specific siRNA (siPrx1)
and the reduction of PRX1 protein levels was validated
by western blot (Fig. 1a and b). Based on the MTT assay,
vitK3 was significantly more efficient at inducing cell
death in PRX1-silenced cells than in control cells trans-
fected with non-targeting pool control siRNA (siCon).
After 4 h of 15 μM vitK3 treatment, viability of PRX1
knockdown HeLa cells was reduced to ~25 %, signifi-
cantly lower than the control cells transfected with
siCon (Fig. 1a). PRX1 knockdown A549 cells were more
resistant (~80 % cell viability) than PRX1 knockdown
HeLa cells (Fig. 1a, b). However, a 24 h treatment with
15 μM vitK3 caused the death of ~80 % of both PRX1-
silenced HeLa and A549 cells compared with control
cells that had a high survival rate (only ~10 % of cell
death). In order to determine the vitK3 cytotoxicity in
non-cancerous cells, siPrx1 or siCon transfected
HUVEC and primary fibroblasts were exposed to differ-
ent concentrations of vitK3 for 4 or 24 h. As shown in
Fig. 1c and d, both PRX1-silenced HUVEC and fibro-
blast cells showed significantly higher resistant to 15 μMvitK3 treatment compared with PRX1-silenced HeLa
and A549 cells. Interestingly, PRX1 knockdown did not
potentiate vitK3 cytotoxic effect in HUVEC and fibro-
blast cells as cell viability was only reduced by ~20 %.
This indicates that PRX1 knockdown confers vitK3 a
cancer-cell-selective cytotoxicity which could be linked
with the intrinsic property of malignant transformation.
In order to decipher the mechanisms underlying
cancer-cell-selective cytotoxicity of vitK3 in PRX1-
silenced cancer cells, we decided to use a cancer cell
model where PRX1 was stably knockdown. To this end,
we employed commercially available HeLa (Prx1–) and
the corresponding control (Prx1+) cell lines. The effi-
ciency of PRX1 knockdown was previously confirmed by
qRT-PCR and western blot [26]. Based on the MTT
assay, Prx1– cells exhibited a significant and highly re-
producible hypersensitivity to vitK3. Similar to transient
knockdown experiments, 4 h treatment with 15 μM
vitK3 killed ~80 % of Prx1– cells while Prx1+ cells were
not or only barely affected; after a 24 h treatment,
~90 % of Prx1– cells were dead, versus ~40 % for Prx1+
cells (Fig. 1e). Clonogenic assay further confirmed the
enhanced vitK3 cytotoxicity in Prx1– cells. The clono-
genic ratio of Prx1– cells was <5 % versus ~50 % for
Prx1+ cells upon exposure to 15 μM vitK3 for 4 h
(Fig. 1f ).
To determine whether the potentiating effect of PRX1
knockdown was specific to vitK3, we compared the cyto-
toxic effect of six known anticancer agents, vinblastine,
taxol, doxorubicin, daunorubicin, actinomycin D, and 5-
fluorouracil, on Prx1+ cells and Prx1– cells. These drugs
have different mechanisms of action: vinblastine and
taxol are microtubule disrupting agents; doxorubicin
and daunorubicin are DNA intercalating agents; actino-
mycin D inhibits DNA transcription; and 5-fluorouracil
arrests cell cycle [30]. Prx1+ and Prx1– cells exhibited a
similar sensitivity to each of these drugs (Fig. 2). We
conclude that both transient and stable PRX1 knock-
down specifically potentiates vitK3 cytotoxicity on can-
cer cell lines employed in this study. This effect might
be due to redox modulation, as vitK3 is the only ROS-
generating agent among the seven drugs tested.
The enhanced sensitivity to vitK3 involves possibly
necroptosis
VitK3 has been reported to induce both apoptosis [31]
and necrosis [32]. We therefore assessed the nature of
the cell death caused by vitK3 in Prx1– cells. TMRM
staining allows monitoring the loss of MMP, which is a
key early event in the process of apoptosis or pro-
grammed necrosis [33, 34]. The presence of 15 μM vitK3
during 4 h led to the loss of MMP that was seen in a sig-
nificant proportion of Prx1– cells (~50 %), but not in
Prx1+ cells (Fig. 3a). Similarly, a 6 h treatment with
Fig. 1 (See legend on next page.)
He et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:152 Page 5 of 13
(See figure on previous page.)
Fig. 1 PRX1 silencing enhances cancer cell sensitivity to vitK3. a–d MTT assay on HeLa (a), A549 (b), HUVEC (c) cells and primary fibroblasts (d)
transiently transfected with PRX1 specific siRNA or control siRNA for 48 h followed by vitK3 treatment with indicated doses for 4 and 24 h. The
inserts are western blot to verify efficiency of PRX1 knockdown in siRNA transfected cells. e MTT assay on HeLa cells with stable PRX1 knockdown
(Prx1–) and non-silenced control cells (Prx1+) treated with indicated doses of vitK3 for 4 and 24 h. f Clonogenic assay for Prx1+ and Prx1– cells
treated with indicated doses of vitK3 for 4 h then recovered for 10 days. Representative scanned images of 6-well plates are presented (left panel).
Clonogenic ratio = (colony number in vitK3-treated sample / colony number in DMSO-treated control sample) (right panel). Data are mean ± SD
of at least three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
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cells in high proportion (>50 %) in the Prx1– but not
Prx1+ cells (Fig. 3b). Taken together, both indicators
suggest a rapid induction of cell death by vitK3 in Prx1–
cells. Time course analysis showed that Prx1– cells
underwent a clear shift from annexin V–/PI– to both
annexin V–/PI+ and annexin V+/PI+ cells without cells
displaying annexin V+/PI– staining (Fig. 3b), which sug-
gests the occurrence of a programmed necrosis-like cell
death, often termed necroptosis [35]. This observation
was confirmed by the absence of vitK3-induced caspase-
3 cleavage, an important executor in both extrinsic and
intrinsic caspase-dependent apoptotic pathways (data
not shown). Although Prx1+ and Prx1– cells both did
not display any significant cleavage of poly (ADP-ribose)
polymerase 1 (PARP1) during vitK3 treatment, we de-
tected a significant increase in protein poly-ADP-
ribosylation in Prx1– cells treated with vitK3 for 30 min
(Fig. 3c). This latter result suggests the presence of anFig. 2 Cell viability of Prx1+ and Prx1– cells in response to different anti-canc
indicated drugs for defined times. Cell viabilities were monitored by MTT cellhyperactivation of PARP1 and further supports the no-
tion that necroptosis constitute the mechanism of vitK3-
induced Prx1– cell death [35].
A major accumulation of H2O2 underlies Prx1– cells
sensitivity to vitK3
H2O2 generation is thought to be a key causative
event in vitK3-induced cell death [13, 36], and the ef-
fect of the PRX1 knockdown might therefore operate
through an increase in cellular H2O2 levels. We first
used redox-sensitive chemical probe carboxy-
H2DCFDA to evaluate general cellular ROS levels
during vitK3 treatment. As show in Fig. 4a, treatment
of 15 μM vitK3 for 4 h led to a strong increase in
DCF fluorescence in Prx1– cells, but not in Prx1+
cells. In contrast, same treatment did not trigger vis-
ible change in DCF fluorescence in HUVEC cells
(Fig. 4b) and in primary fibroblasts (data not shown)
with or without PRX1 knockdown. Therefore,er drugs. Both Prx1+ and Prx1– cells were treated with different doses of
viability assay. Data are mean ± SD of at least 2 independent experiments
Fig. 3 VitK3-induced cytotoxicity in Prx1– cells involves necroptosis-like death. a Detection of MMP by TMRM in cells exposed to vitK3 at indicated
time points. One set of three independent results is presented. b Time course of annexin V/PI double staining in cells exposed to 15 μM vitK3. One
representative set of dot plots is presented to show distribution of different cell populations at indicated time points. Percentage of each population is
indicated. c Detection of PARP1 cleavage and PAR activation by western blot in the presence of indicated concentrations of vitK3 for defined times
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Fig. 4 VitK3-induced ROS accumulation in Prx1– cells. a–b Measurement of intracellular ROS level using carboxy-H2DCFDA in Prx1+ and Prx1–
HeLa cells (a) and in siPrx1- and siCon-treated HUVEC cells (b) after 15 μM vitK3 treatment. Results are plotted as cell counts versus fluorescence
intensity. Gray shade, red line, green line, black dotted line and black solid line indicate the fluorescence intensity of the cells before treatment
and after vitK3 treatment for 0.5, 1, 2 and 4 h, respectively. One set of three independent experiments is presented. c Fluorescence microscope
and image analysis of cells expressing cyto-, nuc- and mito-HyPer. The time point before the addition of vitK3 is set as “0”. At upper panel, the
upper and middle rows show acquired images under the YFPex/YFPem and the CFPex/YFPem channels. The lower row of images represents
distribution of HyPer ratio. Scale bar = 6 μm. The color scale for the ratio values represents arbitrary unit of the spectrum, with less oxidized HyPer
in green and highly oxidized HyPer in peak red. At lower panel, time course for the F/F0 ratio values (see Materials and Methods) in single cell
expressing cyto-, nuc- or mito-HyPer during vitK3 treatment is presented. Fluorescence intensity of HyPer was recorded every 10 s over 5 min
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response to vitK3 are correlated with their different
degrees of sensitivity to vitK3.
To get insights into the dynamics of H2O2 accumu-
lation and its cellular compartmentation following
vitK3 treatment, we used variants of the H2O2-spe-
cific sensor HyPer targeted to cytosol, nucleus or
mitochondrial matrix (designated cyto-, nuc- and
mito-HyPer) [27]. Fluorescence intensity of HyPer was
recorded every 10 s upon vitK3 treatment. In Prx1–
cells all three compartments displayed rapid and sig-
nificant increase in fluorescence intensity, detectable
1 min after addition of vitK3 (Fig. 4c), while in Prx1+
cells no such increase was seen. We also recorded the
time course oxidation of HyPer over 60 min in the
presence of 15 μM vitK3 by separating the reduced
versus oxidized forms of the probe by redox westernblot (Fig. 5a). In Prx1– cells, addition of vitK3 caused
a gradual oxidation/reduction of the HyPer over time
in the three compartments, which started at 1 min
and plateaued after about 10 min in the nucleus and
mitochondria and at 20 min in the cytosol. It is
worth noting that the oxidation of HyPer probe was
much higher in mitochondria (~60 % at plateau) than
in the cytosol (~25 % at 60 min) and nucleus (~30 %
at plateau). In contrast, in each of the three compart-
ments of Prx1+ cells exposed to vitK3, oxidation of
HyPer was never over half of the oxidation seen in
Prx1– cells. Both fluorescence microscopy and redox
western blots suggest that vitK3 induces a rapid accu-
mulation of H2O2 in all three compartments
inspected, and that this accumulation is significantly
higher in Prx1– cells, particularly in the mitochon-
drial matrix.
Fig. 5 (See legend on next page.)
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Fig. 5 Oxidation of HyPer, endogenous TRX1, TRX2 and PRX3 monitored by redox western blot. a Oxidation of HyPer in response to vitK3 treatment.
Cells expressing respectively cyto-, nuc- and mito-HyPer were treated with 15 μM vitK3 for indicated times and then subjected to redox western blots.
Quantifications are mean ± SD of at least three independent experiments. b Redox western blot for TRX1 and TRX2. Cells treated with 15 μM vitK3 for
indicated times were subjected to redox protein extraction and AMS treatment. Lane PC presents TRX1 oxidation in H2O2-treated Prx1+ cells as
positive control. Quantifications are mean ± SD of at least three independent experiments. c Redox western blot for PRX3. Redox protein extraction
was treated with NEM. Monomer and dimer forms are indicated. d NAC suppresses vitK3 toxicity. Cells were pretreated with 10 mM NAC for 2 h prior
to incubation with freshly prepared medium containing both 10 mM NAC and 15 μM vitK3 for additional 4 h. Cell viability was determined by MTT
assay (upper panel). e NAC suppresses vitK3-induced ROS accumulation. Global ROS levels were monitored by carboxy-H2DCFDA (left panel). Gray
shade, black solid line, and black dotted line indicate the fluorescence intensity of the control cells, cells treated with 15 μM vitK3 alone for 4 h, and
cells treated with 10 mM NAC and 15 μM vitK3 for 4 h, respectively. Compartment-specific H2O2 levels in Prx1– cells were monitored by HyPer probes
(right panel). Redox state of HyPer in Prx1– cells treated with 15 μM vitK3 for 60 min was used as positive control. *P≤ 0.05, **P≤ 0.01, ***P≤ 0.001
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upon vitK3 treatment on the expression and redox states
of the cytosolic (TRX1) and mitochondrial (TRX2) thior-
edoxins and of PRX3 which is a peroxiredoxin located in
the mitochondrial matrix and a major H2O2-scavenging
enzyme within this compartment [37, 38]. As shown in
Fig. 5b, TRX1 and TRX2 were mostly in the reduced
form in both Prx1+ and Prx1– cells, TRX1 remained re-
duced upon addition of vitK3 while TRX2 became oxi-
dized up to 50 % in Prx1– cells. On the other hand,
TRX1 and TRX2 protein levels, which were initially ele-
vated in Prx1– cells compared with Prx1+ cells, de-
creased by 2–3 fold upon drug treatment whereas they
remained constant in Prx1+ cells (Fig. 5b). PRX3 levels
were not different between Prx1– and Prx1+ cells; how-
ever the enzyme underwent rapid oxidation upon drug
treatment, as manifested by the apparition of character-
istic disulfide-linked dimers, and this oxidation was
more pronounced in Prx1– cells (Fig. 5c). In summary,
vitK3 treatment leads to pronounced redox alterations
in Prx1– cells, including H2O2 accumulation, TRX2 and
PRX3 oxidation, and a decrease in the protein levels of
both TRX1 and TRX2. All may contribute to an en-
hanced vitK3 cytotoxicity.
To assess the causative role of ROS in vitK3-induced
cell death, we tested the effect of the antioxidant NAC
on cell survival. The addition of 10 mM NAC nearly
completely prevented vitK3-induced death of Prx1– cells
(Fig. 5d). NAC also prevented the accumulation of ROS
and more specifically H2O2 after vitK3 treatment, as re-
vealed by carboxy-H2DCFDA fluorescence and by the
redox state of HyPer probes (Fig. 5e). These data
strongly suggest that the increased ROS accumulation in
Prx1– cells has a causative role in vitK3-induced cell
death.
Enhanced sensitivity to vitK3 in Prx1– cells relies on
NQO2 expression
Previous studies have demonstrated that NQO2 activ-
ity, which reduces vitK3 to its hydroquinone form
without the formation of a semiquinone radical inter-
mediate, is required for vitK3 redox cycling andcytotoxicity [1]. qRT-PCR and western blot analyses
revealed that mRNA and protein levels of NQO2
were significantly up-regulated in Prx1– cells com-
pared with control cells (Fig. 6a). To test whether the
higher NQO2 levels in Prx1– cells could account for
the enhanced toxicity of vitK3 in these cells, the
NQO2 inhibitor quercetin [39, 40] was added prior to
vitK3 treatment. Quercetin significantly attenuated
vitK3-induced cell death and vitK3-induced ROS ac-
cumulation (Fig. 6b). These data confirm the implica-
tion of NQO2 in vitK3-induced cytotoxicity.
Discussion
Rational drug combinations directed against multiple
targets are effective anticancer strategies, by preventing
cancer drug resistance and allowing the use of lower
therapeutic drug posologies, thus overcoming the side
effects of high doses of the single drugs. In the present
study, we showed that PRX1 knockdown significantly
and specifically potentiates vitK3 cellular sensitivity,
which allows the reduction of the doses necessary to kill
cancer cells. MTT and clonogenic assays, TMRM and
annexin V/PI double staining all demonstrated that a
24 h treatment with 15 μM vitK3 is enough to trigger
cell death and kill a significant proportion of PRX1
knockdown cancer cells. Importantly, such treatments
caused little apparent reduction in cell viability of non-
cancerous cells, with or without PRX1 knockdown. This
indicates that vitK3 has a cancer-cell-selective cytotoxic
property, in particular when PRX1 activity is
compromised.
Using recently developed redox analysis tools, we
demonstrated that 15 μM vitK3 triggered a rapid and
significant accumulation of H2O2 in the mitochondrial
matrix, cytosol and nucleus in Prx1– cells. This ROS ac-
cumulation of H2O2 played a determinant role in en-
hanced vitK3-induced cell death. Up-regulation of
NQO2 in Prx1– cells appears to contribute to the in-
creased H2O2 generation in the presence of vitK3. How
PRX1 knockdown leads to the up-regulation of NQO2
remains unknown. NQO2 gene contains the antioxidant
response element (ARE) in its promotor region and is
Fig. 6 Increased expression of NQO2 in Prx1– cells accounts for
enhanced cell death in response to vitK3 treatment. a NQO2 mRNA
and protein levels were detected by qRT-PCR and western blot,
respectively. The inserts are western blot detecting NQO2. The
cropped blot images for NQO2 and loading controls are from same
western blot. Quantifications are mean ± SD of three independent
experiments. b Inhibition of NQO2 activity attenuated vitK3 toxicity.
Cells pretreated with quercetin (NQO2 inhibitor) were exposed to a
combination of quercetin and vitK3. Cell viability was determined
by MTT assay. Data are mean ± SD of at least three independent
experiments. Global ROS levels were monitored by carboxy-
H2DCFDA staining. Gray shade, gray solid line, black solid line,
and black dotted line indicate the fluorescence intensity of the
control cells, cells treated with quercetin alone for 4 h, cells
treated with vitK3 alone for 4 h, and cells treated with quercetin
and vitK3 for 4 h, respectively. **P ≤ 0.01
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is possible that PRX1 knockdown causes redox imbal-
ance that up-regulates the expression of some Nrf2-
regulated ARE-containing genes including NQO2.
NQO2 catalyzes metabolic activation of vitK3 leading to
cytotoxicity, in contrast to NADPH:quinone oxidoreduc-
tase (NQO1) that metabolically detoxifies vitK3 andprotects cells against oxidative stress [1]. As 15 μM
vitK3 induced only minor ROS accumulation and cyto-
toxicity in Prx1+ cells, we propose that the rapid and
important ROS elevation in Prx1– cells could be derived
from a combined effect of an increased H2O2 generation
during vitK3 metabolism by higher NQO2 activity and a
decreased PRX1 scavenging activity. Enhanced H2O2 ac-
cumulation in Prx1– cells upon vitK3 treatment is de-
tected in the three subcellular compartments analyzed
with a marked effect on mitochondrion. This was con-
firmed by the oxidation of TRX2 and PRX3, two major
mitochondrial redox-maintaining-antioxidant proteins
[42], which may reflect a widespread mitochondrial pro-
tein oxidation and is likely to further facilitate H2O2 ac-
cumulation in mitochondria, leading eventually to cell
death.
VitK3 and β-lapachone (β-lap) both trigger remarkable
accumulation of H2O2 in PRX1 knockdown HeLa cells
[26]. However, although these two quinones are sup-
posed to share similar redox cycling pathways, they im-
plicate different mechanisms. ROS accumulation in
vitK3-treated and β-lap-treated Prx1– cells depends on
NQO2 and NQO1, respectively. In particular, NQO1
catalyzes a two-electron reduction of both vitK3 and β-
lap [43]. While vitK3 is detoxified by NQO1 [44], β-lap
toxicity is strongly potentiated by this enzyme activity
[45]. On the other hand, inhibition of NQO2 (present
study) or the absence of NQO2 (NQO2-null mice) con-
fers resistance to vitK3-induced oxidative stress and
cytotoxicity [1]. The role of NQO2 in β-lap toxicity
remains unknown. Nonetheless, we observed that quer-
cetin, a NQO2 inhibitor, significantly attenuated β-lap-
induced cell death (data not shown), indicating the
enhancing role of NQO2 in both β-lap and vitK3 cyto-
toxicity. In addition to distinct metabolisms related to
ROS generation, the downstream events and signaling
pathways that lead to cell death in response to β-lap and
to vitK3 seems to be different. Among the MAPK path-
ways analyzed, JNK, p38 and ERK are highly phosphory-
lated after β-lap treatment and JNK activation plays a
critical role in mediating low-dose β-lap-induced cell
death in Prx1– cells [26]. However, an equivalent lethal
dose of vitK3 results in moderate ERK phosphorylation
that does not influence vitK3-induced Prx1– cell death
(data not shown). It will be interesting to identify the
distinct mechanisms of action of these two related quin-
one molecules, linking ROS accumulation and down-
stream signaling pathways.
VitK3-induced cancer-cell-selective toxicity is consistent
with the notion that cancer cells usually display persistent
pro-oxidative state. As such, cancer cells would be more
dependent on the antioxidant system to maintain the ROS
levels below the toxic threshold, and therefore more vul-
nerable to further oxidative stress induced by exogenous
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Our current findings further support the view that modu-
lation of intracellular redox states is a viable alternative
approach to enhance cancer cell sensitivity to ROS-
generating drugs, or to overcome some types of drug re-
sistance [14, 15]. Elevated expression of PRX1 has fre-
quently been found in various cancer cells [22, 24] and
PRX1 is responsible for cell resistance to TRAIL and cis-
platin [25, 46]. Therefore, PRX1 is an interesting target in
an oxidative stress-modulating anticancer strategy. From
this study, it is reasonable to expect a reduction of ~40 to
~50 % of vitK3 doses when administrated with an efficient
PRX1 inhibitor, with better anti-cancer efficiency and less
side effects. As no specific PRX1 inhibitor is currently
commercially available, the reported peroxiredoxin inhibi-
tors such as Conoidin A and Adenanthin inhibit preferen-
tially peroxiredoxin 2 and affect other antioxidant
pathways [47–49], the use of such inhibitors is less appeal-
ing for the establishment of a PRX1-based redox antican-
cer therapeutic strategy. Our data obtained by specific
PRX1 knockdown approach provide a proof of concept
that PRX1 could be an interesting anticancer target lead-
ing to a substantial reduction of the vitamin K3 dosage to
kill cancer cells. The development of new specific and effi-
cient PRX1 inhibitors could open new avenues for redox-
based anticancer therapies.
Conclusion
Killing cancer cells by a ROS-mediated mechanism has
received increasing attention recently. However, due to
the presence of redox adaptation mechanisms, the use of
ROS-generating agents alone may not be sufficient to
efficiently kill cancer cells exhibiting up-regulated anti-
oxidants. Redox modulation of cancer cells by PRX1
knockdown confers enhanced sensitivity to vitK3
through increased ROS accumulation. PRX1 could be an
anticancer target leading to a substantial reduction of
the vitK3 dosage to kill cancer cells. Conceptually, a
combination of drugs that modulate intracellular redox
states and drugs that operate through the generation of
ROS could be a new therapeutic strategy for cancer
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